PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studiesFLORHAM PARK, N.J., July 14, 2022 (GLOBE...
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
• Phase 1 dose-escalation study started at clinical sites in the U.S. • Milestone demonstrates CureVac’s and GSK’s continued execution...
∙ The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics ∙ CureVac RNA Printer...
Rolling submission to accelerate time to marketing authorization of CVnCoV in SwitzerlandReview process started with submission of first CVnCoV data...
Lessons from the most important tech adoption of our century: the COVID-19 vaccine By Cameron Turner, VP Data Science and...
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV ∙ Induction of robust antibody and T cell responses...